Literature DB >> 28516749

International Comparison of Adult Height in Children with Growth Hormone Deficiency and Limitations of Growth Hormone Treatment in Japan.

Toshiaki Tanaka1.   

Abstract

The approved therapeutic dose of growth hormone (GH) for growth hormone deficiency (GHD) varies depending on the country. Japan has the lowest therapeutic dose globally, with a single dose of 0.175 mg/kg/week. GH treatment for GHD is considered as a replacement therapy and in fact, a dose of 0.175 mg/kg/week is slightly higher than GH secretion in prepubertal healthy children but nearly the same as that of pubertal children. Although the same growth rate as that of healthy children is expected in response to replacement therapy, the catch-up growth observed for the first 1 to 2 years of GH treatment was misinterpreted as an effect of the GH replacement therapy. The real effect of the GH replacement therapy was the growth rate appeared after more than 3 years of GH therapy, when patients showed nearly the same growth rate as healthy children. Therefore, children with GHD can have a higher growth rate than healthy children only for the first 1 to 2 years of GH therapy, after which their growth rate begins to wane. In the United States and Europe, the various therapeutic doses and high-dose treatment are accepted and the SD score of adult height after treatment is higher than that in Japan. The improvement degree of the height SD score and the adult height SD score with GH therapy are lower in Japan compared with other countries that administer a similar therapeutic dose. This suggests that the response to GH can be affected by race. Actual comparison of the response to GH between Japanese and Caucasian patients using KIGS (Pharmacia International Growth Database) data showed that both the short-term response and the effect on adult height were reduced in Japanese patients. As there is a strong positive correlation between adult height and height at the onset of puberty, treatment methods that can increase pubertal growth will be considered in the future for patients with GDH who enter puberty with short stature. Copyright© of YS Medical Media ltd.

Entities:  

Keywords:  Adult height; GH dose; GH treatment; GHD; GnRH analog combination therapy

Mesh:

Substances:

Year:  2017        PMID: 28516749     DOI: 10.17458/per.vol14.2017.t.internationalcomparison

Source DB:  PubMed          Journal:  Pediatr Endocrinol Rev        ISSN: 1565-4753


  2 in total

Review 1.  Short and Long-Term Effects of Growth Hormone in Children and Adolescents With GH Deficiency.

Authors:  Michael B Ranke
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

2.  Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.

Authors:  Reiko Horikawa; Toshiaki Tanaka; Yukihiro Hasegawa; Tohru Yorifuji; David Ng; Ron G Rosenfeld; Yuko Hoshino; Akifumi Okayama; Daisuke Shima; Roy Gomez; Aleksandra Pastrak; Orlando Castellanos
Journal:  Horm Res Paediatr       Date:  2022-04-13       Impact factor: 4.275

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.